2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2374 Engineering CST6N137D enhances CAR-T cell persistence and protects against multiple myeloma-induced bone disease

Yamin Meng, PhD, MIN Yang, PhD2, Jieqiong Zhou, MD3, Michael Blackburn, PhD4, Hongwei Xu, MD5, Zijun Zhang, PhD6, Yan Cheng, PhD7, Majid Asgari, PhD8, David E. Mery, PhD9, Hannah Cutshall, MD10, Daisy Alapat, M.D.11, Carolina D Schinke, MD12, Jin-Ran Chen, MD,PhD13, Eric Siegel, MS14, Frits van Rhee, MD, PhD15, John D Shaughnessy, Jr, PhD16, Guido Tricot, MD/PhD17, Fenghuang Zhan, MD/PhD18
1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
5 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
6 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
7 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
8 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
9 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
10 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
11 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
12 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
13 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
14 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
15 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
16 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
17 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
18 Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Introduction

Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable clinical success in hematological malignancies. Despite high initial response rates, limited CAR T persistence and progressive dysfunction remain major barriers to durable responses. Multiple myeloma (MM) is characterized by the accumulation of monoclonal plasma cells and the development of osteolytic bone lesions. We previously showed that engineering BCMA-CAR-T cells to secrete wild-type cystatin E/M (BCMA/CST6WT) alleviates myeloma-induced bone disease. However, CST6WT failed to enhance the antitumor efficacy of BCMA-CAR-T cells. Moreover, CST6WT induces M2 macrophage polarization and T-cell immunosuppression. We hypothesized that, because CST6N137D preserves the bone-protective properties of CST6WT while eliminating its immunosuppressive effects on T cells, engineering CAR-T cells to secrete CST6N137D (BCMA/CST6N137D) would improve their durability and antitumor efficacy.

Methods

Human BCMA-CAR-T cells expressing CST6WT or CST6N137D were generated by lentiviral transduction. Antitumor efficacy of CAR-T cells was assessed using cytotoxicity assays. T-cell activation, memory status, exhaustion, and CAR surface expression were analyzed by flow cytometry. Therapeutic efficacy and CAR-T-cell persistence were evaluated in MM xenograft models. The effects of CST6N137D on MM-associated bone disease were analyzed using micro-computed tomography (μCT) and TRAP staining analysis.

Results

Compared with CST6WT, CST6N137D significantly enhanced the cytotoxicity of BCMA-CAR-T cells against MM cell lines at effector-to-target (E/T) ratios ranging from 1:5 to 5:1 and increased expression of CD69, IFN-γ, and IL-2 following antigen stimulation for 24 h, indicating improved anti-tumor efficacy. Furthermore, CST6N137D significantly increased the frequencies of central memory T cells while reducing expression of exhaustion markers, including PD-1, TIGIT, TIM3, and LAG3, demonstrating that CST6N137D effectively reverses CST6WT-induced T-cell dysfunction and promotes a more durable and functional phenotype.

A prominent feature of BCMA/CST6N137D-CAR-T cells was the preservation of CAR surface expression during chronic antigen stimulation. Although both CST6WT and CST6N137D inhibited CAR downmodulation following short-term antigen exposure, CST6N137D maintained significantly higher CAR surface expression and proliferative capacity during long-term tumor exposure.

We next evaluated the in vivo efficacy of BCMA/CST6N137D-CAR-T cells. In the MM xenograft model, BCMA/CST6N137D-CAR-T cells demonstrated more durable tumor clearance than BCMA/CST6WT-CAR-T cells did. Mice treated with BCMA/CST6N137D-CAR-T cells showed a substantially reduced tumor burden in the bone marrow, spleen, and peripheral blood, together with increased CAR-T-cell persistence. Remarkably, approximately 25% of mice treated with BCMA/CST6N137D-CAR-T cells were completely protected after tumor rechallenge. CST6N137D fully retained the bone-protective activity of CST6WT and effectively suppressed myeloma-induced osteolytic bone destruction while substantially enhancing CAR-T-cell function.

Mechanistically, transcriptomic and functional analyses identified c-FOS as a key regulator of the enhanced BCMA/CST6N137D-CAR-T-cell efficacy. Compared with CST6WT, CST6N137D upregulated c-FOS in BCMA-CAR-T cells, thereby promoting memory differentiation, limiting T-cell exhaustion, and enhancing antitumor activity, consistent with c-FOS-mediated functional reprogramming of CAR-T cells.

Conclusions

Engineering BCMA-CAR-T cells secreting CST6N137D significantly enhances CAR-T persistence, inhibits CAR downmodulation, limits immune dysfunction, and improves antitumor efficacy while maintaining protection against myeloma-associated bone destruction. Mechanistically, CST6N137D promotes c-FOS-dependent functional reprogramming to sustain long-term CAR-T-cell efficacy. These findings identify CST6N137D as a promising CAR-T strategy capable of simultaneously targeting tumor burden and disease-associated bone disease in multiple myeloma, supporting its preclinical and translational development.

Yamin Meng, PhD: No relevant conflicts of interest to declare.